Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165906 | 1.00 | OXTR (0.87) | OXTRAVPR2 | |
| Retosiban SCHEMBL21255735 | 0.93 | OXTR (1.00) | OXTRAVPR2 | |
| Retosiban SCHEMBL20240377 | 0.93 | OXTR (1.00) | OXTRAVPR2 | |
| Retosiban SCHEMBL29376892 | 0.93 | OXTR (1.00) | OXTRAVPR2 | |
| Retosiban SCHEMBL5224662 | 0.93 | OXTR (1.00) | OXTRAVPR2 | |
| Retosiban SCHEMBL230301 | 0.93 | OXTR (1.00) | OXTRAVPR2 | |
| SCHEMBL5420881 | 0.88 | OXTR (0.68) | OXTRAVPR2 | |
| SCHEMBL3929376 | 0.86 | OXTR (1.00) | OXTRAVPR2 | |
| SCHEMBL5164527 | 0.85 | OXTR (1.00) | OXTRAVPR2 | |
| SCHEMBL5432398 | 0.85 | OXTR (1.00) | OXTRAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185162-A1 | Substituted diketopiperazines as oxytocin receptor antagonists | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2007-08-09 | — | — | US | claimed |
| US-20070185162-A1 | Substituted diketopiperazines as oxytocin receptor antagonists | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185162-A1 | Substituted diketopiperazines as oxytocin receptor antagonists | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| US-20070185162-A1 | Substituted diketopiperazines as oxytocin receptor antagonists | KONINKLIJKE PHILIPS ELECTRONICS, N.V. (NL) | 2007-08-09 | — | — | US | disclosed |
| EP-1768974-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006000759-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006000759-A1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185162-A1 | Substituted diketopiperazines as oxytocin receptor antagonists | OXTR, AVPR2, PRLHR | OXTR 1/4885AVPR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.